| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Deoxycorticosterone-d8 targets mineralocorticoid receptors (MRs) in target cells, such as those in the kidneys. As a potent mineralocorticoid, it binds to these receptors and exerts its effects by modulating gene expression. It is virtually devoid of glucocorticoid activity. The compound acts on mineralocorticoid receptors, leading to activation of signaling cascades that regulate sodium and potassium ion transport. It is also a precursor molecule for the production of aldosterone, the primary mineralocorticoid.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, deoxycorticosterone-d8 is not used for activity studies but rather as an internal standard. The non-deuterated compound, deoxycorticosterone, is used to study mineralocorticoid receptor activation in cell-based assays. It stimulates sodium reabsorption and potassium excretion in renal epithelial cell lines (e.g., MDCK cells). It also influences gene expression of sodium channels (ENaC) and Na+/K+-ATPase. The deuterated version is used as a tracer in quantitative LC-MS assays. |
| ln Vivo |
In vivo, deoxycorticosterone-d8 is not administered for pharmacological studies. The non-deuterated deoxycorticosterone is used in animal models to induce hypertension and electrolyte imbalance. For example, DOCA-salt hypertensive rats are a classic model of mineralocorticoid-induced hypertension. In these studies, deoxycorticosterone acetate (DOCA) is administered subcutaneously (25-50 mg/kg) combined with high-salt diet, leading to sodium retention, increased blood pressure, and cardiac hypertrophy. The deuterated standard can be used to quantify DOC levels in these models.
|
| Enzyme Assay |
For non-cellular assays (analytical quantification), deoxycorticosterone-d8 is prepared as a stock solution in methanol (1 mg/mL). For LC-MS/MS analysis, a calibration curve for deoxycorticosterone is prepared in human serum or plasma (0.1-100 ng/mL) with a fixed concentration of deoxycorticosterone-d8 (e.g., 10 ng/mL). Sample extraction: 500 uL plasma + 25 uL internal standard solution + 2 mL methyl tert-butyl ether (MTBE). Extract is vortexed, centrifuged, and the organic layer is evaporated to dryness. The residue is reconstituted in 100 uL methanol and injected onto a C18 column (2.1×50 mm, 1.8 um) with a mobile phase of 0.1% formic acid in water and methanol (70:30 isocratic or gradient).
|
| Cell Assay |
For cell-based assays, MDCK cells or HEK293 cells stably expressing mineralocorticoid receptors (MR) are used. Cells are seeded in 24-well plates (1×10⁵ cells/well) in DMEM without phenol red, supplemented with charcoal-stripped FBS. After 24 hours, cells are treated with deoxycorticosterone (0.1 nM-10 uM) for 24-48 hours. Reporter gene assays: for MR transactivation, cells are co-transfected with a luciferase reporter (e.g., MMTV-Luc) and an MR expression plasmid. After treatment, luciferase activity is measured. Gene expression of ENaC (alpha, beta, gamma subunits) and Na+/K+-ATPase is quantified by qPCR.
|
| Animal Protocol |
For in vivo animal experiments, DOCA-salt hypertensive model is used. Male Sprague-Dawley rats (8-10 weeks old) undergo uninephrectomy. One week later, DOCA (deoxycorticosterone acetate, 25-50 mg/kg) is administered subcutaneously (silicone pellet implant or twice-weekly injection) and animals are given 1% NaCl drinking water and standard chow for 4-6 weeks. Blood pressure is measured weekly by tail-cuff or telemetry. Urine is collected in metabolic cages to measure sodium and potassium excretion. At the end of the study, plasma renin activity, aldosterone levels, and electrolyte concentrations are measured. For quantification of DOC levels, deoxycorticosterone-d8 is used as an internal standard in LC-MS analysis of plasma samples.
|
| ADME/Pharmacokinetics |
Deoxycorticosterone-d8 has a molecular formula of C21H22D₈O3 and a molecular weight of approximately 338.51. It is a white solid powder soluble in DMSO and organic solvents (ethanol, methanol). The compound should be stored at -20degC in a sealed container, protected from moisture and light. As a deuterium-labeled compound, it is non-radioactive and chemically stable. Deuteration improves analytical sensitivity and precision in mass spectrometry due to the mass shift.
|
| Toxicity/Toxicokinetics |
Deoxycorticosterone-d8 is a stable isotope-labeled compound with low toxicity at analytical concentrations (ng-ug per sample). The non-deuterated parent compound, deoxycorticosterone, at high doses can cause hypertension, sodium retention, and potassium loss. However, when used as an internal standard, the amount is negligible and poses no toxicity risk. Standard laboratory safety precautions for handling steroid hormones should be followed (use of PPE, avoid inhalation/ingestion).
|
| References | |
| Additional Infomation |
See also: Desoxycortone (note moved to).
Deoxycorticosterone-d8 is an analytical standard and research tool, not an approved drug. It is not intended for therapeutic use and has no clinical trials. The non-deuterated parent compound, deoxycorticosterone (acetate), has been used clinically in the past as a mineralocorticoid for adrenal insufficiency but has largely been replaced by fludrocortisone. Deoxycorticosterone-d8 is used exclusively as an internal standard for quantifying deoxycorticosterone in biological samples by LC-MS/MS. It is used in research for studying steroidogenesis, mineralocorticoid receptor function, and electrolyte balance. |
| Molecular Formula |
C21H22D8O3
|
|---|---|
| Molecular Weight |
338.51
|
| Exact Mass |
338.269
|
| CAS # |
55487-63-3
|
| Related CAS # |
Deoxycorticosterone;64-85-7
|
| PubChem CID |
223578
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
488.0±45.0 °C at 760 mmHg
|
| Melting Point |
132-134ºC
|
| Flash Point |
263.0±25.2 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
606
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZESRJSPZRDMNHY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H30O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h11,15-18,22H,3-10,12H2,1-2H3
|
| Chemical Name |
17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9541 mL | 14.7706 mL | 29.5412 mL | |
| 5 mM | 0.5908 mL | 2.9541 mL | 5.9082 mL | |
| 10 mM | 0.2954 mL | 1.4771 mL | 2.9541 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
